Capillary malformations, from genotype to phenotype: a focus on endothelial functio
Recruiting
- Conditions
- Capillary malformationport wine stain1004078910047043
- Registration Number
- NL-OMON49348
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Adult patients with capillary malformations currently undergoing lasertherapy
at the Amsterdam UMC location AMC.
Exclusion Criteria
Children and incapacitated patienten.
Patients with a mix of different vascular malformations.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameter is the presence of the GNAQ, GNA11, RASA1 or PIK3CA<br /><br>gene mutation in study participants. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary parameter is the biochemical profile, barrier function,<br /><br>angiogenic sprouting capacity and wound healing properties of endothelial cells<br /><br>from blood vessels of port wine stains. </p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do RASA1 mutations influence endothelial dysfunction in capillary malformations (NL-OMON49348)?
What comparative effectiveness data exist for laser therapy versus pharmacological agents in port wine stain management (ACME study)?
Which biomarkers (e.g., CD31, VEGF) correlate with treatment response in capillary malformation patients (NCT049348)?
What adverse events are reported in endothelial-targeted therapies for port wine stains (NL-OMON49348 observational study)?
How do RAS pathway inhibitors like sirolimus compare to propranolol in capillary malformation treatment (ACME study context)?